Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06122662 · ClinicalTrials.gov registry record · Phase 2
AMX0035 and Progressive Supranuclear Palsy
A Phase 2 study of Progressive Supranuclear Palsy and Neurodegenerative Diseases, sponsored by Amylyx Pharmaceuticals.
- Active
- Registry status
- Phase 2
- Development phase
- 110
- Enrollment target
- 20
- Study locations
NCT06122662 is a Phase 2 study of Progressive Supranuclear Palsy and Neurodegenerative Diseases that is active but no longer recruiting, run by Amylyx Pharmaceuticals. The registered enrollment target is 110 participants, below the 446-participant average among 18 other Progressive Supranuclear Palsy trials with a reported enrollment target (75% lower). The trial reports 20 study locations across 13 states.
The verdict
NCT06122662, a Phase 2 study of Progressive Supranuclear Palsy and Neurodegenerative Diseases, is active but no longer recruiting, sponsored by Amylyx Pharmaceuticals.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 110 participants
- Enrollment target
- 20
- Study locations
Study Summary
A35-009 (ORION) is a Phase 2b/3 trial to evaluate the efficacy and safety of AMX0035 in participants with Progressive Supranuclear Palsy (PSP), consisting of randomized, double blind placebo controlled phases, followed by an optional open-label extension phase.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG AMX0035
Study Locations (20)
California
- Parkinson's & Movement Disorder Institute - Fountain Valley
- University of Southern California - Los Angeles
- Cedars Sinai Medical Center - Los Angeles
- Stanford Movement Disorder Center - Palo Alto
- University of California, San Francisco (UCSF) - San Francisco
Florida
- Parkinson's Disease and Movement Disorders Center of Boca Raton - Boca Raton
- UF Health Dorothy Mangurian Neuroimaging Suite - Gainesville
- Mayo Clinic Florida - Jacksonville
Massachusetts
- Massachusetts General Hospital - Boston
- Lahey Hospital and Medical Center - Burlington
Arizona
- Mayo Clinic - Scottsdale
Arkansas
- University of Arkansas for Medical Sciences - Little Rock
Colorado
- UC Health Anschutz Outpatient Pavilion Anschutz Medical Campus - Aurora
Georgia
- Augusta University - Augusta
Hawaii
- Parkinsons and Movement Disorder Center at the Queens Medical Center - Honolulu
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 110 participants |
| Start Date | 2023-12-21 |
| Est. Completion | 2029-11-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06122662
The ClinicalTrials.gov registry entry for NCT06122662 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 110 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 446-participant average among 18 other Progressive Supranuclear Palsy trials with a reported enrollment target (75% lower). The listed sponsor is Amylyx Pharmaceuticals, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Progressive Supranuclear Palsy appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06122662 reports 20 study locations spanning 13 distinct geographic areas - top geographies include California, Florida, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06122662 about?
NCT06122662 is a clinical study titled "AMX0035 and Progressive Supranuclear Palsy". A35-009 (ORION) is a Phase 2b/3 trial to evaluate the efficacy and safety of AMX0035 in participants with Progressive Supranuclear Palsy (PSP), consisting of randomized, double blind placebo controlled phases, followed by an optional open-label extension phase.
What is the current status of trial NCT06122662?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 110 participants. The study started on 2023-12-21. Estimated completion is 2029-11-30.
What conditions does trial NCT06122662 study?
This clinical trial studies the following conditions: Progressive Supranuclear Palsy, Neurodegenerative Diseases, PSP, Atypical Parkinsonism.
What interventions are being tested in trial NCT06122662?
The interventions under investigation include: Placebo (OTHER), AMX0035 (DRUG).
Who is sponsoring clinical trial NCT06122662?
This trial is sponsored by Amylyx Pharmaceuticals, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06122662 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Progressive Supranuclear Palsy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Assess the Efficacy, Safety, and Pharmacokinetics of FNP-223 to Slow Progression of Progressive Supranuclear Palsy (PSP)
ACTIVE NOT RECRUITING · Phase 2
-
Effects of Coenzyme Q10 in PSP and CBD
COMPLETED · Phase 2
-
Study to Evaluate the Safety and Efficacy of Davunetide for the Treatment of Progressive Supranuclear Palsy
COMPLETED · Phase 2
-
Investigating Complex Neurodegenerative Disorders Related to Amyotrophic Lateral Sclerosis and Frontotemporal Dementia
RECRUITING
-
Gait Analysis in Neurological Disease
RECRUITING
-
A Molecular Anatomic Imaging Analysis of Tau in Progressive Supranuclear Palsy
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.